{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:46:09Z","timestamp":1776653169052,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40266-025-01232-2","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T18:02:53Z","timestamp":1753380173000},"page":"879-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum Concentration of Apixaban in Relation to Renal Function in Older Hospitalized Patients"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2354-8701","authenticated-orcid":false,"given":"Trude Cecilie","family":"Mellings\u00e6ter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole Martin","family":"Steihaug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"4","key":"1232_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Cecilia Bahit M, Benz AP, Bohula EA, Chao TF, Dyal L, Ezekowitz M, Fox KAA, Gencer B, Halperin JL, Hijazi Z, Hohnloser SH, Hua K, Hylek E, Toda Kato E, Kuder J, Lopes RD, Mahaffey KW, Oldgren J, Piccini JP, Ruff CT, Steffel J, Wojdyla D, Granger CB. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355.","journal-title":"Circulation"},{"key":"1232_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.amjcard.2023.07.108","volume":"204","author":"KY Fong","year":"2023","unstructured":"Fong KY, Chan YH, Yeo C, Lip GYH, Tan VH. Systematic review and meta-analysis of direct oral anticoagulants versus warfarin in atrial fibrillation with low stroke risk. Am J Cardiol. 2023;204:366\u201376. https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.108.","journal-title":"Am J Cardiol"},{"issue":"4","key":"1232_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/jcph.2184","volume":"63","author":"LV Bortman","year":"2023","unstructured":"Bortman LV, Mitchell F, Naveiro S, et al. Direct oral anticoagulants: an updated systematic review of their clinical pharmacology and clinical effectiveness and safety in patients with nonvalvular atrial fibrillation. J Clin Pharmacol. 2023;63(4):383\u201396. https:\/\/doi.org\/10.1002\/jcph.2184.","journal-title":"J Clin Pharmacol"},{"key":"1232_CR4","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.15420\/ecr.2021.55","volume":"17","author":"HN Tun","year":"2022","unstructured":"Tun HN, Kyaw MT, Rafflenbeul E, Su\u00e1stegui XL. Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis. Eur Cardiol. 2022;17:e11. https:\/\/doi.org\/10.15420\/ecr.2021.55. (Published 2022 May 13).","journal-title":"Eur Cardiol"},{"issue":"3","key":"1232_CR5","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.injury.2021.11.052","volume":"53","author":"CJ Nederpelt","year":"2022","unstructured":"Nederpelt CJ, Bijman Q, Krijnen P, Schipper IB. Equivalence of DOACS and LMWH for thromboprophylaxis after hip fracture surgery: systematic review and meta-analysis. Injury. 2022;53(3):1169\u201376. https:\/\/doi.org\/10.1016\/j.injury.2021.11.052.","journal-title":"Injury"},{"issue":"4","key":"1232_CR6","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.OA.23.00064","volume":"8","author":"AM Negm","year":"2023","unstructured":"Negm AM, Yamaura L, Clarke A, Chaudhry D, Cherppukaran T, Schneider P. Effectiveness of thromboprophylaxis agents following hip fracture: a systematic review and network meta-analysis. JB JS Open Access. 2023;8(4): e23.00064. https:\/\/doi.org\/10.2106\/JBJS.OA.23.00064.","journal-title":"JB JS Open Access"},{"issue":"12","key":"1232_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2010","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2010;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561. (Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877).","journal-title":"N Engl J Med"},{"issue":"10","key":"1232_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKETAF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638. (Epub 2011 Aug 10).","journal-title":"N Engl J Med"},{"issue":"11","key":"1232_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039. (Epub 2011 Aug 27).","journal-title":"N Engl J Med"},{"key":"1232_CR10","unstructured":"Reseptregisteret, FHI, https:\/\/www.reseptregisteret.no [search Nov 11th, 2020] (the Norwegian Prescription database, http:\/\/www.norpd.no)."},{"key":"1232_CR11","unstructured":"European Medicines Agency (EMA), Eliquis, INN-apixaban. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf."},{"issue":"3","key":"1232_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-024-01466-0","volume":"64","author":"NN Ngcobo","year":"2025","unstructured":"Ngcobo NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clin Pharmacokinet. 2025;64(3):335\u201367. https:\/\/doi.org\/10.1007\/s40262-024-01466-0. (Epub 2025 Jan 11. Erratum in: Clin Pharmacokinet. 2025 Mar;64(3):463. 10.1007\/s40262-025-01494-4).","journal-title":"Clin Pharmacokinet"},{"issue":"17","key":"1232_CR13","doi-asserted-by":"publisher","first-page":"E612","DOI":"10.1503\/cmaj.221427","volume":"195","author":"AA Merchant","year":"2023","unstructured":"Merchant AA, Ling E. An approach to treating older adults with chronic kidney disease. CMAJ. 2023;195(17):E612\u20138. https:\/\/doi.org\/10.1503\/cmaj.221427.","journal-title":"CMAJ"},{"issue":"1","key":"1232_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6\u201314. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02007.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1232_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40266-018-0609-4","volume":"36","author":"KK Viktil","year":"2019","unstructured":"Viktil KK, Lehre I, Ranhoff AH, Molden E. Serum concentrations and elimination rates of direct-acting oral anticoagulants (DOACs) in older hip fracture patients hospitalized for surgery: a pilot study. Drugs Aging. 2019;36(1):65\u201371. https:\/\/doi.org\/10.1007\/s40266-018-0609-4.","journal-title":"Drugs Aging"},{"issue":"10","key":"1232_CR16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidb\u00fcchel H, External reviewers (2021). 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065. (Erratum in: Europace. 2021 Oct 9;23(10):1676. 10.1093\/europace\/euab157).","journal-title":"Europace"},{"issue":"8","key":"1232_CR17","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3390\/biomedicines10082001","volume":"10","author":"S Limcharoen","year":"2022","unstructured":"Limcharoen S, Pongchaidecha M, Pimsi P, Limprasert S, Suphanklang J, Saelim W, Santimaleeworagun W, Boonmuang P. Do apixaban plasma levels relate to bleeding? The clinical outcomes and predictive factors for bleeding in patients with non-valvular atrial fibrillation. Biomedicines. 2022;10(8):2001. https:\/\/doi.org\/10.3390\/biomedicines10082001.","journal-title":"Biomedicines"},{"issue":"1","key":"1232_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5853\/jos.2020.04952","volume":"24","author":"T Rizos","year":"2022","unstructured":"Rizos T, Meid AD, Huppertz A, Dumschat C, Purrucker J, Foerster KI, Burhenne J, Czock D, Jenetzky E, Ringleb PA, Haefeli WE. Low exposure to direct oral anticoagulants is associated with ischemic stroke and its severity. J Stroke. 2022;24(1):88\u201397. https:\/\/doi.org\/10.5853\/jos.2020.04952. (Epub 2022 Jan 31).","journal-title":"J Stroke"},{"issue":"5","key":"1232_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","volume":"2","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review. JAMA Cardiol. 2017;2(5):566\u201374. https:\/\/doi.org\/10.1001\/jamacardio.2017.0364.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"1232_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3949\/ccjm.70.4.361","volume":"70","author":"A Jaffer","year":"2003","unstructured":"Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med. 2003;70(4):361\u201371. https:\/\/doi.org\/10.3949\/ccjm.70.4.361.","journal-title":"Cleve Clin J Med"},{"key":"1232_CR21","doi-asserted-by":"publisher","unstructured":"Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring.\u00a0Proceedings (Baylor University. Medical Center). 2001;14(3), 305\u2013306. https:\/\/doi.org\/10.1080\/08998280.2001.11927781.","DOI":"10.1080\/08998280.2001.11927781"},{"issue":"2","key":"1232_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40266-022-00999-y","volume":"40","author":"A Eidam","year":"2023","unstructured":"Eidam A, Marji J, Benzinger P, Foerster KI, Burhenne J, Czock D, Stoll F, Blank A, Mikus G, Haefeli WE, Bauer JM. Frailty as a marker for the plasma concentrations of direct oral anticoagulants in older patients: results of an exploratory study. Drugs Aging. 2023;40(2):153\u201364. https:\/\/doi.org\/10.1007\/s40266-022-00999-y. (Epub 2023 Jan 13).","journal-title":"Drugs Aging"},{"issue":"9","key":"1232_CR23","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41374-021-00610-9","volume":"101","author":"T Xun","year":"2021","unstructured":"Xun T, Lin Z, Wang X, Zhan X, Feng H, Gan D, Yang X. Advanced oxidation protein products downregulate CYP1A2 and CYP3A4 expression and activity via the NF-\u03baB-mediated signaling pathway in vitro and in vivo. Lab Invest. 2021;101(9):1197\u2013209. https:\/\/doi.org\/10.1038\/s41374-021-00610-9. (Epub 2021 May 24).","journal-title":"Lab Invest"},{"issue":"10","key":"1232_CR24","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1023\/a:1026135317578","volume":"20","author":"B Rege","year":"2003","unstructured":"Rege B, Krieg R, Gao N, Sarkar MA. Down-regulation of hepatic CYP3A in chronic renal insufficiency. Pharm Res. 2003;20(10):1600\u20136. https:\/\/doi.org\/10.1023\/a:1026135317578.","journal-title":"Pharm Res"},{"issue":"4","key":"1232_CR25","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/cpt.1875","volume":"108","author":"EJ Egeland","year":"2020","unstructured":"Egeland EJ, Witczak BJ, Zar\u00e9 HK, Christensen H, \u00c5sberg A, Robertsen I. Chronic inhibition of CYP3A is temporarily reduced by each hemodialysis session in patients with end-stage renal disease. Clin Pharmacol Ther. 2020;108(4):866\u201373. https:\/\/doi.org\/10.1002\/cpt.1875. (Epub 2020 Jun 1).","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1232_CR26","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1124\/dmd.117.078030","volume":"45","author":"K Hole","year":"2017","unstructured":"Hole K, St\u00f8rset E, Olastuen A, Haslemo T, Kro GB, Midtvedt K, \u00c5sberg A, Molden E. Recovery of CYP3A phenotype after kidney transplantation. Drug Metab Dispos. 2017;45(12):1260\u20135. https:\/\/doi.org\/10.1124\/dmd.117.078030. (Epub 2017 Sep 19).","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1232_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002512-199507010-00003","volume":"7","author":"S Gupta","year":"1995","unstructured":"Gupta S. P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging. 1995;7(1):19\u201329. https:\/\/doi.org\/10.2165\/00002512-199507010-00003.","journal-title":"Drugs Aging"},{"issue":"6","key":"1232_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.clpt.2006.02.004","volume":"79","author":"R Toornvliet","year":"2006","unstructured":"Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood\u2013brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79(6):540\u20138. https:\/\/doi.org\/10.1016\/j.clpt.2006.02.004.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01232-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01232-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01232-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:40:41Z","timestamp":1757922041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01232-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01232-2","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"3 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial or not for profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors T.C.M. and O.M.S. have no conflicts of interest to report. E.M. received lecturing fees from Lundbeck and Outsuka Pharmaceutical Co. The authors did not receive support from any organization for the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Regional Committee for Medical and Health Research Ethics (REK number 2019\/1193) and conducted in accordance with the declaration of Helsinki. The project was approved by the medical director on behalf of the hospital prior to study initiation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The plans for data protection, confidentiality and privacy were reviewed and approved by the Regional Committee for Medical and Health Research Ethics.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data protection, confidentiality, and privacy"}},{"value":"All participating patients signed the written informed consent approved by the Regional Committee for Medical and Health Research Ethics.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The datasets generated during and\/or analyzed during the current study are not authorized to be publicly available under the current ethics approval. However, any queries regarding the datasets generated and analyzed for this project may be directed to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All authors contributed to the study concept and design. T.C.M. was responsible for data collection, and all authors contributed to data analysis. The first draft of the manuscript was written by T.C.M., with major edits made by E.M. and O.M.S. All authors reviewed and commented on previous versions of the manuscript and approved the final version. All authors have reviewed and approved the final submitted manuscript and agree to be accountable for its content.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}